Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial

被引:0
|
作者
Chen Chen [1 ]
Liang Huizhu [2 ]
He Meibo [3 ]
Duan Ruqiao [1 ]
Guan Yu [4 ]
Wang Fangfang [5 ]
Duan Liping [1 ]
机构
[1] Department of Gastroenterology, Peking University Third Hospital, Beijing, China
[2] Department of Cardiology, Peking University People’s Hospital, Beijing, China
[3] Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
[4] Department of Cardiology, Beijing Haidian Hospital, Beijing, China
[5] Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing,
关键词
Proton pump inhibitors; Histamine-2 receptor antagonists; Acute coronary syndrome; Gut microbiota;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
摘要
Background: Several randomized controlled studies have suggested that the prophylactic use of proton pump inhibitors (PPIs) in intensive care unit (ICU) patients could not reduce the incidence of gastrointestinal bleeding (GIB) and may increase adverse events such as intestinal infection and pneumonia. Gut microbiota may play a critical role in the process. PPIs have been widely prescribed for GIB prophylaxis in patients with acute coronary syndrome (ACS). This study aimed to determine the short-term effects of PPI and histamine-2 receptor antagonist (H2RA) treatment on gut microbiota of ACS patients.Methods: The study was designed as a single-blind, multicenter, three-parallel-arm, randomized controlled trial conducted at three centers in Beijing, China. We enrolled ACS patients at low-to-medium risk of GIB and randomized (2:2:1) them to either PPI (n = 40), H2RA (n = 31), or control group (n = 21). The primary outcomes were the alterations in gut microbiota after 7 days of acid suppressant therapy. Stool samples were collected at baseline and 7 days and analyzed by 16S ribosomal RNA (rRNA) gene sequencing.Results: There were no significant changes in the diversity of gut microbiota after the short-term use of acid suppressants, but the abundance ofFusobacterium significantly increased and that ofBifidobacterium significantly decreased, especially in PPI users. In addition, the abundance of some pathogenic bacteria, includingEnterococcus andDesulfovibrio, was significantly elevated in the PPI users. The fecal microbiota of the PPI users included more arachidonic acid metabolism than that of control group.Conclusions: PPIs may increase the risk of infection by adversely altering gut microbiota and elevating arachidonic acid metabolism, which may produce multiple proinflammatory mediators. For ACS patients at low-to-medium risk of GIB, sufficient caution should be paid when acid-suppressant drugs are prescribed, especially PPIs.Registration: www.chictr.org.cn (ChiCTR2000029552).
引用
收藏
相关论文
共 50 条
  • [41] Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults-a meta-analysis of randomized controlled trials with trial sequential analysis
    Zhou, Xiaoyang
    Fang, Hanyuan
    Xu, Jianfei
    Chen, Peifu
    Hu, Xujun
    Chen, Bixin
    Wang, Hua
    Hu, Caibao
    Xu, Zhaojun
    BMC GASTROENTEROLOGY, 2019, 19 (01)
  • [42] Impact of short-term endothelin-A receptor blockade on plasma markers for remodeling in patients with ST-elevation acute coronary syndrome
    Wurm, R.
    Adlbrecht, C.
    Andreas, M.
    Redwan, B.
    Distelmaier, K.
    Klappacher, G.
    Lang, I. M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S2 - S3
  • [43] Impact of short-term endothelin-A receptor blockade on plasma markers for remodeling in patients with ST-elevation acute coronary syndrome
    Wurm, R.
    Adlbrecht, C.
    Andreas, M.
    Redwan, B.
    Distelmaier, K.
    Klappacher, G.
    Lang, I. M.
    EUROPEAN HEART JOURNAL, 2013, 34 : 410 - 410
  • [44] Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
    Camaro, Cyril
    Damen, Sander A. J.
    Brouwer, Marc A.
    Kedhi, Elvin
    Lee, Stephan W.
    Verdoia, Monica
    Barbieri, Lucia
    Rognoni, Andrea
    vant Hof, Arnoud W. J.
    Ligtenberg, Erik
    de Boer, Menko-Jan
    Suryapranata, Harry
    De Luca, Giuseppe
    AMERICAN HEART JOURNAL, 2016, 178 : 37 - 44
  • [45] Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease
    Sigterman, Kirsten E.
    van Pinxteren, Bart
    Bonis, Peter A.
    Lau, Joseph
    Numans, Mattijs E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (05):
  • [46] Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease
    van Pinxteren, Bart
    Sigterman, Kirsten E.
    Bonis, Peter
    Lau, Joseph
    Numans, Mattijs E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (11):
  • [47] Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease
    van Pinxteren, B.
    Numans, M. E.
    Bonis, P. A.
    Lau, J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03):
  • [48] Effect of Ticagrelor Compared to Clopidogrel on Short-term Outcomes of COVID-19 Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Interven-tion; a Randomized Clinical Trial
    Arefizadeh, Reza
    Moosavi, Seyed Hossein
    Towfiqie, Sayied
    Mohsenizadeh, Seyed Abolfazl
    Pishglfi, Mehdi
    ARCHIVES OF ACADEMIC EMERGENCY MEDICINE, 2023, 11 (01)
  • [49] An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
    Lopes, Renato D.
    Vora, Amit N.
    Liaw, Danny
    Granger, Christopher B.
    Darius, Harald
    Goodman, Shaun G.
    Mehran, Roxana
    Windecker, Stephan
    Alexander, John H.
    AMERICAN HEART JOURNAL, 2018, 200 : 17 - 23
  • [50] Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial
    Kedhi, Elvin
    Verdoia, Monica
    Suryapranata, Harry
    Damen, Sander
    Camaro, Cyril
    Benit, Edouard
    Barbieri, Lucia
    Rasoul, Saman
    Liew, Houng B.
    Polad, Jawed
    Ahmad, Wan A. W.
    Zambahari, Robaayah
    Lalmand, Jacques
    van der Schaaf, Rene J.
    Koh, Tian H.
    Timmermans, Philippe
    Dilling-Boer, Dagmara
    Veenstra, Leo F.
    van' t Hof, Arnoud W. J.
    Lee, Stephen W. L.
    Roolvink, Vincent
    Ligtenberg, Erik
    Postma, Sonja
    Kolkman, Evelien J. J.
    Brouwer, Marc A.
    Dudek, Dariusz
    De Luca, Giuseppe
    ATHEROSCLEROSIS, 2021, 321 : 39 - 44